Efficacy and Risk Factors Associated to Resistance to Single-Agent Chemotherapy in Low-Risk Gestational Trophoblastic Neoplasia
2016
Objectives: This study aimed to assess efficacy of
intramuscular methotrexate 8-day protocol in the treatment of low-risk
gestational trophoblastic neoplasia and also identify prognostic factors
associated with treatment failure, necessitating second line chemotherapy.
Methods: This study was performed at Gynaecologic and Obstetric Clinic of Dakar
Teaching Hospital, the reference Centre of Gestational Trophoblastic Disease in
Senegal. At the beginning of 2011, patients were followed according to FIGO’s
recommendations. From 2011 to 2014, we diagnosed 88 low-risk gestational
trophoblastic neoplasia (GTN) patients (WHO score < 7). Low-risk patients
started their treatment with methotrexate (MTX) based on the 8-day protocol
consisting of 1 mg/kg MTX in combination with 0.1 mg/kg folinic acid (FA) every
other day. Resistance to treatment was the main outcome. We studied the
association of different prognostic factors included in the World Health
Organisation (WHO) scoring system and resistance to the initial single agent chemotherapy.
Results: Eighty-eight patients were diagnosed for GTN during the study period.
Average age was 31 years. The antecedent pregnancy was molar in 98.1% of cases.
Seventy-four patients underwent remission after single agent-chemotherapy.
Resistance rate to single-agent chemotherapy was 15.9% (14 patients). Nine of
them achieved remission after second line chemotherapy. WHO score was
significantly associated with the risk of resistance to single-agent
chemotherapy. Other variables included in the WHO as age, antecedent pregnancy,
pre-treatment hCG, tumour size and FIGO stage were not significantly associated
with resistance. We report five fatal cases. Conclusion: The 8-day protocol
consisting of 1 mg/kg MTX in combination with 0.1 mg/kg folinic acid (FA) every
other day is effective for women with LRGTN. The only significant prognostic
factor for failure is pretreatment WHO score. We highly recommend the use of
this protocol particularly in developing countries where methotrexate is
available, affordable and relatively safe.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
10
References
0
Citations
NaN
KQI